Payment overview · 2025
General Payments
$1,083.16
56 reported records · 15 companies
Healthcare provider profile · identity verified
Susan C Mcmullen, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GUN BARREL CITY, TX · NPI 1699758136
Verified facts
What the public records show
CMS Open Payments records show Susan C Mcmullen, M.D. received $1,083.16 in general payments during 2025 across 56 reported records.
GlaxoSmithKline, LLC. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $205.84 | 19.0% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $148.93 | 13.8% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $107.11 | 9.9% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $88.11 | 8.1% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.09 | 6.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $70.61 | 6.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $67.25 | 6.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.74 | 6.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $57.87 | 5.3% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $54.37 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $38.62 | 3.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $38.49 | 3.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.61 | 2.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.00 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.52 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,083.16 | 56 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $205.84 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.88 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $88.11 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $81.14 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $72.09 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $70.61 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $65.74 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.01 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $54.37 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $51.10 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $38.49 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.72 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 143 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 199 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 200 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
73 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
118 | 38 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
200 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
165 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 45 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
143 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1087 | 311 |
| Gabapentin | Gabapentin | 764 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 676 | 175 |
| Losartan Potassium | Losartan Potassium | 651 | 200 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 645 | 88 |
| Omeprazole | Omeprazole | 552 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 543 | 152 |
| Lisinopril | Lisinopril | 501 | 150 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 499 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 474 | 128 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 452 | 156 |
| Metformin Hcl | Metformin Hcl | 414 | 117 |
| Trazodone Hcl | Trazodone Hcl | 349 | 107 |
| Furosemide | Furosemide | 331 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 286 | 75 |
| Potassium Chloride | Potassium Chloride | 282 | 86 |
| Montelukast Sodium | Montelukast Sodium | 264 | 73 |
| Prednisone | Prednisone | 254 | 146 |
| Escitalopram Oxalate | Escitalopram Oxalate | 242 | 74 |
| Pravastatin Sodium | Pravastatin Sodium | 241 | 72 |
| Sertraline Hcl | Sertraline Hcl | 240 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 229 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 224 | 89 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 200 | 54 |
| Jardiance | Empagliflozin | 199 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 53 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 191 | 66 |
| Meloxicam | Meloxicam | 185 | 66 |
| Ozempic | Semaglutide | 180 | 45 |
| Aripiprazole | Aripiprazole | 171 | 46 |
| Tramadol Hcl | Tramadol Hcl | 170 | 41 |
| Trulicity | Dulaglutide | 165 | 35 |
| Carvedilol | Carvedilol | 164 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 159 | 41 |
| Bupropion Xl | Bupropion Hcl | 158 | 47 |
| Alendronate Sodium | Alendronate Sodium | 156 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 156 | 44 |
| Simvastatin | Simvastatin | 156 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 149 | 41 |
| Glimepiride | Glimepiride | 147 | 44 |
| Eliquis | Apixaban | 143 | 45 |
| Ezetimibe | Ezetimibe | 141 | 46 |
| Memantine Hcl | Memantine Hcl | 140 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 46 |
| Allopurinol | Allopurinol | 132 | 40 |
| Famotidine | Famotidine | 130 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 130 | 34 |
| Pregabalin | Pregabalin | 129 | 49 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 37 |
| Fluoxetine Hcl | Fluoxetine Hcl | 127 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 36 |
| Promethazine Hcl | Promethazine Hcl | 118 | 19 |
| Synthroid | Levothyroxine Sodium | 118 | 38 |
| Alprazolam | Alprazolam | 117 | 23 |
| Buspirone Hcl | Buspirone Hcl | 114 | 35 |
| Spironolactone | Spironolactone | 113 | 35 |
| Estradiol | Estradiol | 109 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 104 | 28 |
| Ondansetron Odt | Ondansetron | 103 | 44 |
| Tresiba Flextouch U-100 | Insulin Degludec | 97 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 32 |
| Clonazepam | Clonazepam | 90 | 12 |
| Methocarbamol | Methocarbamol | 89 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 35 |
| Mirtazapine | Mirtazapine | 81 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 81 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 28 |
| Azithromycin | Azithromycin | 80 | 65 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 80 | 22 |
| Celecoxib | Celecoxib | 79 | 23 |
| Lorazepam | Lorazepam | 77 | 25 |
| Fluconazole | Fluconazole | 76 | 39 |
| Nystatin | Nystatin | 76 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 75 | 22 |
| Baclofen | Baclofen | 74 | 23 |
| Linzess | Linaclotide | 73 | 24 |
| Cephalexin | Cephalexin | 72 | 58 |
| Mounjaro | Tirzepatide | 68 | 14 |
| Topiramate | Topiramate | 68 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 67 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 48 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 65 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 12 |
| Ibuprofen | Ibuprofen | 62 | 22 |
| Propranolol Hcl | Propranolol Hcl | 62 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 59 | 18 |
| Lidocaine | Lidocaine | 59 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 39 |
| Januvia | Sitagliptin Phosphate | 57 | 17 |
| Atenolol | Atenolol | 56 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 47 |
| Colestipol Hcl | Colestipol Hcl | 56 | 22 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 55 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 54 | 18 |
| Amoxicillin | Amoxicillin | 53 | 42 |
| Humalog Kwikpen U-100 | Insulin Lispro | 53 | 20 |
| Diazepam | Diazepam | 52 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 51 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 15 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 16 |
| Donepezil Hcl | Donepezil Hcl | 48 | 18 |
| Lamotrigine | Lamotrigine | 48 | 11 |
| Meclizine Hcl | Meclizine Hcl | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 48 | 15 |
| Valacyclovir | Valacyclovir Hcl | 48 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 47 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 13 |
| Acyclovir | Acyclovir | 45 | 17 |
| Xarelto | Rivaroxaban | 45 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 44 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 33 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 11 |
| Benazepril Hcl | Benazepril Hcl | 42 | 11 |
| Glipizide | Glipizide | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | 12 |
| Lovastatin | Lovastatin | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Naproxen | Naproxen | 38 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 15 |
| Nitroglycerin | Nitroglycerin | 37 | 25 |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 13 |
| Lubiprostone | Lubiprostone | 35 | suppressed |
| Myrbetriq | Mirabegron | 35 | 12 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 34 | 16 |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Carisoprodol | Carisoprodol | 31 | suppressed |
| Clotrimazole | Clotrimazole | 31 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | 14 |
| Anastrozole | Anastrozole | 30 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Mupirocin | Mupirocin | 29 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Prolia | Denosumab | 29 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | 11 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Metronidazole | Metronidazole | 24 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 23 | 16 |
| Finasteride | Finasteride | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 20 |
| Temazepam | Temazepam | 22 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 20 |
| Primidone | Primidone | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Acetazolamide | Acetazolamide | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Testosterone | Testosterone | 15 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Tretinoin | Tretinoin | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clarithromycin | Clarithromycin | 12 | 12 |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,083.16 · 56 records | GlaxoSmithKline, LLC. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, IBSRELA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, RELISTOR, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRULANCE, VRAYLAR, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error